Combining traditional Chinese medicine may offer potential therapeutic value in treating both Alzheimer's disease and major depressive disorder simultaneously.
Researchers leveraged network pharmacology and molecular docking technology to identify the effect of traditional Chinese medicine and its multitarget components for treating Alzheimer's disease and major depressive disorder. They analyzed 234 TCM prescriptions for major depressive disorder, identifying the top 10 most commonly used herbs, reflecting 198 active ingredients. They then did comparative analysis for prospective ingredient targets related to both disorders. The analysis included exploring common and key targets and representative compounds for effective treatment. The combination of Xiangfu (Cyperi Rhizoma), Gancao (Licorice) and Chaihu (Radix Bupleuri) constituted the major component of representative ingredients that were analyzed.
The results yielded the identification of 30 common targets, 9 key targets, and 7 representative compounds relevant to both disorders. Their findings revealed these common targets were essential to regulate multiple pathways linked to both disorders, emphasizing the potential for a cohesive treatment approach. Furthermore, molecular docking studies unveiled the binding affinity of several natural chemicals, including quercetin, kaempferol, β-sitosterol, stigmasterol, isorhamnetin, naringenin, and 8-isopentenyl-kaempferol, with key prospective targets. This suggests that a TCM combination could provide therapeutic advantages in treating both Alzheimer's disease and major depressive disorder.
